POC, the Non Invasive Alternative for Diagnostics
With non-communicable diseases (NCDs) now constituting the majority of global mortality, there is a growing need for low-cost, noninvasive methods to diagnose and treat this class of diseases, especially in resource-limited settings. In line with the same, Serascience Limited, a specialist cancer diagnostics company established by a joint venture between Abingdon Health and the University of Birmingham, announced the receipt of European CE Mark approval for the commercial sale of Seralite, its proprietary point-of-care diagnostic device for multiple myeloma.
View full press release